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Summary
Large-scale analysis directly at the protein level holds the
promise of uncovering features not apparent or present at
the gene level [1–3]. Although mass spectrometry (MS)-
based proteomics can now identify and quantify thousands
of cellular proteins in large-scale proteomics experiments,
much of the peptide information contained in these experi-
ments remains unassigned [4]. Here, we use such informa-
tion to discover a previously unreported mechanism
creating altered protein forms. Linker histones H1 and
high-mobility group (HMG) proteins are abundant nuclear
proteins that regulate gene expression through modulation
of chromatin structure [5–8]. In the high-resolution MS anal-
ysis of histone H1 and HMG protein fractions isolated from
human cells, we discovered peptides that mapped upstream
of the known translation start sites of these genes. No alter-
native upstream start site exists in the genome, but analysis
of Expressed Sequence Tag (EST) databases revealed that
these N-terminally extended (ET) proteins are due to in-
frame translation of the 50 untranslated region (50UTR) se-
quences of the transcripts. The new translation start sites
are created by a single uridine insertion between AG, reflect-
ing a previously unreported RNA-editing mechanism. To our
knowledge, this is the first report of RNA-insertion editing in
humans and may be an example of the type of discoveries
possible with modern proteomics methods.
Results and Discussion
Identification of N-Terminally Extended (ET) Proteins
In-depth proteomic analysis of nuclear extracts from various
human cell lines revealed a multitude of posttranslational mod-
ifications in linker histone H1 and high-mobility group (HMG)
proteins [9]. Apart from this, we found a number of fragmenta-
tion spectra of excellent quality that could not be matched to
any protein sequence or open reading frame (ORF) in the
*Correspondence: mmann@biochem.mpg.de (M.M.), jwisniew@biochem.
mpg.de (J.R.W.)human International Protein Index (IPI) database. We therefore
extracted partial de novo sequences from these fragmentation
spectra. When searching the NCBI dbEST database [10] with
these sequences, we found that they matched directly up-
stream of the start codon and within the 50UTR of h1.0. Simi-
larly, we also found peptides pertaining to the 50UTR of the
hmgn1 gene. This was surprising because in both cases, the
50UTRs do not contain any alternative start codons.
To characterize the N-terminally extended (ET) sequences of
H1.0 and HMGN1, we partially purified these proteins from
MCF7 cells by reversed-phase chromatography, resolved frac-
tions by SDS PAGE (Figure 1A), digested them with trypsin, and
analyzed peptide mixtures by online liquid-chromatography
mass spectrometry (LCMS). We identified a total of eight
unique peptides (including one phosphopeptide) of ET-H1.0
and two unique peptides of ET-HMGN1 using high-resolution,
high-mass-accuracy MS. Several of these peptides were
further verified by high-resolution fragmentation analysis with
low ppm accuracy (see Appendices S1 and S2, available on-
line). Fragmentation spectra of the identified peptides contain-
ing the ‘‘normal’’ initiation methionine, as well as the peptides
most proximal to the N termini of ET-H1.0 and ET-HMGN1,
are shown in Figure 1. We identified two forms of ET-H1.0, vis-
ible as two bands in SDS PAGE, and a single form of ET-HMGN1
(Figure 1F). On the basis of the mapped peptides, the long and
short ET extensions of H1.0 comprise at least 86 and 63 amino
acid residues, respectively, whereas the ET extension of
HMGN1 is at least 23 amino acid residues in length. Due to their
amino acid composition, the high number of the basic residues,
and the low number of the hydrophobic residues, histones have
reduced mobility in SDS PAGE. With respect to the molecular
weight (MW) markers, H1 histones appear at a MW of 30,000–
35,000 Da. However, their molecular masses are in the range
of 20,000–22,000 Da. This is the reason that the ET-H1.0 forms
appear to have MWs close to 40,000 Da.
New Translation Start Sites Are Created
by a Single Uridine Insertion
We then searched the NCBI dbEST database for EST frag-
ments containing the 50UTR of h1.0 and found 11 sequences,
derived from different tissue sources, with a uridine (U) inser-
tion (the NCBI dbEST database release of August 06, 2008
contains 301 ESTs carrying the h1.0 50UTR, 11 of them with
U insertion). In each case, this insertion happened at the
same position—297 bp upstream of the known start codon—
between the A and G bases at the AGCT location (Figure 2B,
Appendices S3, S4, and S5). For hmgn1, we likewise found
an EST sequence in which a new start codon is potentially cre-
ated by U insertion, in this case 135 nt upstream of the known
start codon (Appendices S3 and S5). With these start sites, the
identified peptides cover 85% and 50% of the predicted se-
quences of ET-H1.0 and ET-HMGN1, respectively (Figure 2A).
h1.0 occurs as a single gene in the genome database. To
exclude the existence of a genomic form of ET-h1.0, we per-
formed PCR analysis of genomic DNA for the sequence sug-
gested by the EST data. The ‘‘normal’’ h1.0 gene has an AluI
restriction site (50-AG/CT-30) in its 50UTR sequence at the posi-
tion where the U insertion was found in some EST sequences
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1762Figure 2. Primary Structure and Putative Origin of ET
Proteins
(A) Schematic view of the proteins with extension of
their termini (ET) originating from translation of the
50UTRs. Black, canonical translation products;
green, sequenced by high-resolution mass spec-
trometry; blue, predicted primary structure of the
ET-H1.0 and ET-HMGN1 proteins.
(B) AGCT site with the T insertion (arrow) in EST se-
quences coding for ET proteins.
(C) The AluI site of the ‘‘normal’’ h1.0 sequence is im-
paired by the creation of the new start codon.
(D) The 200 bp sequence containing the base inser-
tion site (red bold) was amplified with genomic DNA
isolated from MCF7 cells. The sequences of the
used primers are underlined.
(E) The 200 bp PCR product was obtained only from
AluI-undigested templates. Lane1, the DNA template
was digested with AluI prior to the PCR reaction;
Lane 2, the PCR reaction with intact template; Lanes
3 and 4, the 200-bp product from lane 2 was ex-
tracted from the gel and incubated in the presence
or absence of AluI, respectively.(Figure 2C). The insertion creates a new start codon and
impairs the AluI-restriction site. Thus, amplification of the
200 bp sequence (Figure 2D) from AluI-treated DNA would
allow identification of the modified fragment, and the PCR
product obtained from the undigested template would be sus-
ceptible toAluI digestion. The PCR reactions revealed that nei-
ther was the 200 bp fragment amplified from the AluI-digested
template nor was the 200 bp PCR product from the undigested
template cleavable by the endonuclease (Figure 2E). These re-
sults disprove the presence of h1.0 gene sequence coding for
N-terminally extended H1.0, confirming that the new start
codon is created during or after transcription of h1.0 by an
RNA editing process. It is possible that the hmgn1 mRNA is
processed by the same mechanism as that of h1.0. While
RNA insertion has not been described in metazoans, it is not
completely unprecedented in biology and may resemble the
RNA editing mechanism described for trypanosomatid proto-
zoans in which the uridine insertion/deletion-based RNA edit-
ing of the mitochondrial mRNA creates new initiation/termina-
tion codons [11]. The resulting N-terminal protein sequences
can carry unique properties such as, for example, DNA binding
[12]. The human 50UTRs of H1.0 and HMGN1 have no obvious
similarities with uridine insertion regions in the trypanosomatid
mitochondrial genes. These regions also are not conserved
between species.
ET Proteins Occur Abundantly in Human Cells
To characterize ET-H1.0 and ET-HMGN1 in human cells and tis-
sues, we raised antibodies in rabbits against peptides derivedfrom the N-terminal extensions and used the affinity-purified
antibodies for western blot and immunofluorescence staining
analyses (Figure 3). The western blot analyses revealed that
both forms of ET-H1.0 were present in human breast- and
lung-cancer cells but not in HeLa cells (Figure 3A). ET-H1.0
was also detected in extracts from three human-cancer tissues
and three normal tissues (Figure 3A). Although ET-H1.0 was al-
ways accompanied by H1.0, its abundance did not correlate
with the observed amounts of H1.0. For example, normal
breast tissue and cancerous breast tissue from the same
patient contained similar amounts of H1.0, whereas the abun-
dance of the ET-H1.0 fluctuated (Figure 3A, lanes 4–9).
Immunofluorescence staining of MCF7 cells revealed
a bright-speckled staining pattern of interphase nuclei (Figures
3B and 3C), and its staining pattern was distinct from that of
H1.0 (Figures 3G and 3H). During mitosis, ET-H1.0 appears to
be in the vicinity of condensed chromosomes (arrows in Figures
3B and 3C). Control staining of HeLa cells, in which we were not
able to detect ET-H1.0 (see above), resulted in the absence of
staining (Figures 3D and 3E). The preferential nuclear location
of ET-H1.0 was confirmed by fractionation of MCF7 cells into
nuclear and low-speed cytosolic fractions followed by western
blotting (Figure 3G). Staining via a monoclonal H1.0 antibody
was distinct from that via its ET form (Figures 3G and 3H).
We found that ET-H1.0 colocalizes with splicing speckles
(Figures 3I–3L). The splicing speckles, subnuclear structures
identified by immunofluorescence microscopy, are thought
to mirror the interchromatin granule clusters detected by elec-
tron microscopy. The most widespread belief is that theFigure 1. Identification of Linker Histone and HMG Proteins with Extra Terminal (ET) Extensions Created upon Translation of the 50-Untranslated Regions
(A) Localization of ET-H1.0 and ET-HMGN1 in PAGE-separated nuclear protein fractions of MCF7 cells.
(B and C) Fragmentation spectra of tryptic peptides carrying the regions from both the ET extension and the ‘‘normal’’ protein parts of ET-H1.0 and
ET-HMGN1, respectively.
(D and E) Fragmentation spectra of tryptic peptides carrying the most N-terminally identified sequences of the ET extension of ET-H1.0 and ET-HMGN1,
respectively. See [25] for explanation of peptide fragmentation.
(F) Putative primary structure of the ET proteins. Bold text indicates experimentally observed ET extension; underlined text indicates sequences of inden-
tified peptides. pS denotes phosphoserine. Negative numbering is used for amino acid residues in the ET extensions. Arrows indicate the primary structures
of the long (l) and short (s) ET-H1.0 forms.
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the needed factors at the demand of the translation machinery
[13]. Even so, with some reports showing that the splicing
speckles could themselves operate as transcription sites
[14], their function remains obscure. A number of nuclear pro-
teins are guided to the speckles through the arginine-and-
serine-rich domain [15]. It is possible that a built-in message
in the ET sequence also directs ET-H1.0 toward the splicing
speckles.
We also performed western blot analyses with the anti-ET-
HMGN1 antibodies. This revealed that ET-HMGN1 is present
in the nuclear fraction of MCF 7 cells and, like ET-H1.0, occurs
in all analyzed normal and cancerous tissues (Figure 3M). We
estimated the relative abundance of ET-HMGN1compared to
HMGN1 to be about 1:50 (Appendix S6).
Abundance of ET-H1.0 Generally Does Not Correlate
with H1.0
Having established the existence and cellular localization of
the ET proteins, we then searched for their possible
Figure 3. Occurrence of ET-H1.0 and ET-HMGN1 in
Human Cells and Tissues
(A) Occurrence of ET-H1.0. Lanes 1–3, western blot
analysis of perchloric acid extracts of cervical-,
breast-, and lung-cancer cells, respectively. Lanes
4–9, extracts of three pairs of tissue, each matching
the same patient (1, 2, or 3), of normal breast
(No) and ductal invasive carcinoma G2 (Ca). Lanes
10 and 11, ovarian tumor. Lanes 11 and 13, normal
colon and colon adenocarcinoma G2. The blots
were probed with anti-ET-H1.0 and H1.0 antibodies.
(B–E) Nuclear localization of ET-H1.0 in MCF7 cells
(B–D); absence of fluorescence in HeLa cells, which
express little or no ET-H1.0 (E); fluorescent staining
of nuclei with DAPI (B and D); and immunofluorescent
staining with anti-ET-H1.0 antibodies (C and E).
(F) Western blot analysis of purified nuclei (lane 2)
and cytosolic fraction (lane 3) of MCF7 cells. Lane
1, perchloric acid extract reference.
(G and H) Double immunofluorescent staining of the
MCF7 nucleus with ET-H1.0 (green) and H1.0 (red)
antibodies, respectively.
(I–L) Double immunofluorescent staining of the MCF7
nucleus with anti-ET-H1.0 (J) and SC-35 (K) anti-
bodies, respectively; DNA staining with DAPI (I);
and merged (J) and (K) (shown in [L]).
(M) Expression of ET-HMGN1. Lanes 1–3 as in (F).
Lanes 4–7, extracts of two pairs, each matching the
same patient (1 or 2), of normal breast (No) and ductal
invasive carcinoma G2 (Ca) tissue samples. Lane 8,
ovarian tumor. Lanes 9 and 10, normal colon and co-
lon adenocarcinoma G2.
regulation in biological processes. Buty-
rate is known to reduce the growth of
many cell types, causing an arrest in the
G1 phase of the cell cycle [16]. In HeLa
S3 cells, the synthesis of H1.0 occurs at
a very low level (mRNA and protein) but
is dramatically augmented by butyrate
treatment [17]. We found that in the buty-
rate-stimulated cells, high expression
levels of H1.0 were accompanied by sub-
stantial increase of ET-H1.0. The increase
was detectable on western blots (Figures
4A and 4B) and by immunofluorescence staining (Figures
4E and 4F).
Given that butyrate has been shown to induce apoptosis in
human cancer cells [18], we decided to analyze the occurrence
of H1.0 and its ET-H1.0 forms upon apoptosis induced by DTT
[19], Vinblastine [20], and TNF-a [21]. Unlike the case of buty-
rate stimulation, in the cells treated with DTT, Vinblastine,
and TNF-a, only ET-H1.0 was augmented. The strongest in-
duction of ET-H1.0 was observed after treatment of the cells
with DTT or TNF-a for 30 hr. In apoptotic cells, ET-H1.0 was
localized in the shrunken and vacuolarized nuclei within the
condensed chromatin, but the ET-H1.0-containing speckles
were also observed outside the nuclei. These results suggest
that the levels of ET-H1.0 are regulated independently of trans-
lation of h1.0 gene. The nature of this regulation mechanism,
as well as a potential role of ET-H1.0 in differentiation and ap-
optosis, remains to be elucidated. Given that the N-terminal-
extension region of ET-H1.0 is highly basic (pI > 12), we spec-
ulate that it could increase the tightness of histone binding to
DNA. In this way, the extension could lead to formation of more
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1764compacted chromatin that is characteristic of both terminally
differentiated and apoptotic cells.
Conclusions
Our work presents strong evidence that some 50-noncoding
sequences of human genes can be translated into proteins
upon creation of the new start codon during or after transcrip-
tion. The N-terminally extended proteins occur in normal hu-
man cells, and their synthesis is not related to alterations at
the DNA level. For the examples described here, the amounts
of ET proteins appear to be about two orders of magnitude
lower than those of the standard products of the correspond-
ing genes. However, given that H1.0 and HMGN1 occur in
about 106–107 copies per cell [22–24], the ET forms are still rel-
atively abundant compared to transcription factors and other
chromatin proteins with specific regulatory functions. Presum-
ably, the ET proteins were not identified until now because
they are not predictable from the corresponding genes and
occur ‘‘in the shadow’’ of their normal forms. Thus, in the
past, the ET proteins were probably observed in many exper-
iments but simply ignored as artifacts. The discovery of two ET
proteins implies the existence of a dedicated enzymatic ma-
chinery of RNA editing, which is probably used more widely.
Modern high-resolution MS data may already contain many
more examples of unexpected protein forms, which could be
brought to light by in-depth informatics analysis.
Experimental Procedures
The experimental procedures are described in the Supplemental Data file,
available online.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and six
appendices and can be found with this article online at http://www.
current-biology.com/S0960-9822(08)01294-3.
Figure 4. In HeLa S3 Cells, ET-H1.0 Can Be Stimulated by Butyrate and
Other Agents, Causing Apoptosis
(A) Western blot analysis of perchloric acid extracts of HeLa S3 cells
treated with butyrate, DTT, Vinblastine, and TNFa. The blots were
probed with anti-ET-H1.0 and H1.0 antibodies.
(B) Western blot analysis of whole lysates of the untreated (lane 1), bu-
tyrate-treated, and DTT-treated cells (24 hr).
(C–H) Immunofluorescence analysis of cells treated with butyrate and
DTT. (C), (E), and (G): anti-ET-H1.0 staining. (D), (F), and (H): merged an-
tibody and DAPI staining.
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